Silence Therapeutics 10% owner Richard Ian Griffiths disposes of ADS-linked common shares worth $16.34 million

Richard Ian Griffiths, a 10% owner of Silence Therapeutics, sold 1,544,374 American Depositary Shares (ADS) between June 29 and July 6, 2026. The transactions occurred at prices ranging from $10.47 to $10.76 per share, totaling approximately $16.34 million. Following these disposals, Griffiths retains indirect beneficial ownership of 10,281,486 ADS. The information was disclosed via a Form 4 filing with the SEC.

Silence Therapeutics Form 4 showed 10% owner Richard Ian Griffiths sold American Depositary Shares from June 29 to July 6, 2026. * Disposals totaled 1,544,374 ADS at prices ranging from $10.47 to $10.76. * Griffiths reported indirect beneficial ownership of 10,281,486 ADS following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080997), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Silence Therapeutics Form 4 showed 10% owner Richard Ian Griffiths sold American Depositary Shares from June 29 to July 6, 2026. * Disposals totaled 1,544,374 ADS at prices ranging from $10.47 to $10.76. * Griffiths reported indirect beneficial ownership of 10,281,486 ADS following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080997), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here